A NOVEL RNA INTERFERENCE THERAPY TO REDUCE CARDIOVASCULAR RISK BY LOWERING LIPOPROTEIN(A) LEVELS USING THE LEPODISIRAN AGENT. jmsi. 2026;5(03):1550-1553. doi:10.55640/